nodes	percent_of_prediction	percent_of_DWPC	metapath
Mivacurium—CHRND—cardiovascular system—attention deficit hyperactivity disorder	0.02	0.109	CbGeAlD
Mivacurium—CHRNA2—forebrain—attention deficit hyperactivity disorder	0.0164	0.0896	CbGeAlD
Mivacurium—CHRNB1—midbrain—attention deficit hyperactivity disorder	0.0101	0.0551	CbGeAlD
Mivacurium—CHRM2—forebrain—attention deficit hyperactivity disorder	0.00978	0.0534	CbGeAlD
Mivacurium—CHRNA2—nervous system—attention deficit hyperactivity disorder	0.0089	0.0486	CbGeAlD
Mivacurium—CHRNA2—central nervous system—attention deficit hyperactivity disorder	0.00857	0.0468	CbGeAlD
Mivacurium—CHRNA2—cerebellum—attention deficit hyperactivity disorder	0.00838	0.0458	CbGeAlD
Mivacurium—CHRM2—cardiovascular system—attention deficit hyperactivity disorder	0.00827	0.0452	CbGeAlD
Mivacurium—CHRNA1—brain—attention deficit hyperactivity disorder	0.0082	0.0448	CbGeAlD
Mivacurium—CHRM3—forebrain—attention deficit hyperactivity disorder	0.00797	0.0435	CbGeAlD
Mivacurium—CHRNB1—cerebellum—attention deficit hyperactivity disorder	0.00779	0.0426	CbGeAlD
Mivacurium—CHRNA2—brain—attention deficit hyperactivity disorder	0.0068	0.0372	CbGeAlD
Mivacurium—BCHE—forebrain—attention deficit hyperactivity disorder	0.0065	0.0355	CbGeAlD
Mivacurium—CHRNB1—brain—attention deficit hyperactivity disorder	0.00633	0.0346	CbGeAlD
Mivacurium—BCHE—cardiovascular system—attention deficit hyperactivity disorder	0.0055	0.03	CbGeAlD
Mivacurium—CHRM2—nervous system—attention deficit hyperactivity disorder	0.00531	0.029	CbGeAlD
Mivacurium—CHRM2—central nervous system—attention deficit hyperactivity disorder	0.00511	0.0279	CbGeAlD
Mivacurium—CHRM3—nervous system—attention deficit hyperactivity disorder	0.00432	0.0236	CbGeAlD
Mivacurium—BCHE—midbrain—attention deficit hyperactivity disorder	0.00429	0.0235	CbGeAlD
Mivacurium—CHRM3—central nervous system—attention deficit hyperactivity disorder	0.00416	0.0228	CbGeAlD
Mivacurium—CHRM2—brain—attention deficit hyperactivity disorder	0.00406	0.0222	CbGeAlD
Mivacurium—BCHE—nervous system—attention deficit hyperactivity disorder	0.00353	0.0193	CbGeAlD
Mivacurium—BCHE—central nervous system—attention deficit hyperactivity disorder	0.0034	0.0186	CbGeAlD
Mivacurium—BCHE—cerebellum—attention deficit hyperactivity disorder	0.00332	0.0182	CbGeAlD
Mivacurium—CHRM3—brain—attention deficit hyperactivity disorder	0.00331	0.0181	CbGeAlD
Mivacurium—CHRM3—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.00328	0.00402	CbGpPWpGaD
Mivacurium—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA4—attention deficit hyperactivity disorder	0.00327	0.00401	CbGpPWpGaD
Mivacurium—CHRM2—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.00325	0.00398	CbGpPWpGaD
Mivacurium—CHRM3—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.00324	0.00397	CbGpPWpGaD
Mivacurium—CHRM2—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.00321	0.00393	CbGpPWpGaD
Mivacurium—BCHE—Transmission across Chemical Synapses—GABRQ—attention deficit hyperactivity disorder	0.00308	0.00378	CbGpPWpGaD
Mivacurium—CHRND—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.00305	0.00373	CbGpPWpGaD
Mivacurium—CHRM3—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.00302	0.0037	CbGpPWpGaD
Mivacurium—CHRNA1—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.00301	0.00369	CbGpPWpGaD
Mivacurium—CHRM2—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.00299	0.00366	CbGpPWpGaD
Mivacurium—CHRM3—Integration of energy metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00297	0.00363	CbGpPWpGaD
Mivacurium—CHRNA2—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.00286	0.0035	CbGpPWpGaD
Mivacurium—CHRND—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.00283	0.00347	CbGpPWpGaD
Mivacurium—CHRND—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00271	0.00332	CbGpPWpGaD
Mivacurium—BCHE—brain—attention deficit hyperactivity disorder	0.0027	0.0147	CbGeAlD
Mivacurium—CHRM3—Regulation of insulin secretion—CACNB2—attention deficit hyperactivity disorder	0.00261	0.00319	CbGpPWpGaD
Mivacurium—CHRNA1—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.00259	0.00317	CbGpPWpGaD
Mivacurium—CHRND—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.00252	0.00309	CbGpPWpGaD
Mivacurium—CHRM3—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.00252	0.00308	CbGpPWpGaD
Mivacurium—CHRM2—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.00249	0.00305	CbGpPWpGaD
Mivacurium—CHRNA2—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.00246	0.00301	CbGpPWpGaD
Mivacurium—CHRNA1—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.00241	0.00295	CbGpPWpGaD
Mivacurium—CHRM3—Regulation of insulin secretion—CACNA1C—attention deficit hyperactivity disorder	0.00238	0.00292	CbGpPWpGaD
Mivacurium—BCHE—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.00236	0.00289	CbGpPWpGaD
Mivacurium—CHRND—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.00233	0.00286	CbGpPWpGaD
Mivacurium—CHRNA1—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00231	0.00282	CbGpPWpGaD
Mivacurium—CHRNA2—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.00229	0.0028	CbGpPWpGaD
Mivacurium—CHRM2—G alpha (i) signalling events—GRM7—attention deficit hyperactivity disorder	0.00228	0.00279	CbGpPWpGaD
Mivacurium—CHRNA2—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00219	0.00268	CbGpPWpGaD
Mivacurium—CHRND—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.00217	0.00266	CbGpPWpGaD
Mivacurium—CHRNA1—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.00215	0.00263	CbGpPWpGaD
Mivacurium—CHRND—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.00215	0.00263	CbGpPWpGaD
Mivacurium—CHRND—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.00213	0.00261	CbGpPWpGaD
Mivacurium—CHRM3—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.00212	0.00259	CbGpPWpGaD
Mivacurium—CHRM2—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.0021	0.00256	CbGpPWpGaD
Mivacurium—CHRM3—Regulation of insulin secretion—SNAP25—attention deficit hyperactivity disorder	0.00208	0.00255	CbGpPWpGaD
Mivacurium—CHRM3—Integration of energy metabolism—CACNB2—attention deficit hyperactivity disorder	0.00205	0.00251	CbGpPWpGaD
Mivacurium—CHRNA2—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.00204	0.0025	CbGpPWpGaD
Mivacurium—CHRNA1—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.00198	0.00243	CbGpPWpGaD
Mivacurium—CHRM3—Regulation of insulin secretion—ADRA2A—attention deficit hyperactivity disorder	0.00198	0.00243	CbGpPWpGaD
Mivacurium—CHRND—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.00193	0.00237	CbGpPWpGaD
Mivacurium—CHRNA2—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.00189	0.00231	CbGpPWpGaD
Mivacurium—CHRM3—Integration of energy metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00187	0.00229	CbGpPWpGaD
Mivacurium—CHRNA1—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.00185	0.00226	CbGpPWpGaD
Mivacurium—CHRNA1—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.00183	0.00223	CbGpPWpGaD
Mivacurium—CHRNA1—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.00181	0.00222	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Other—DRD3—attention deficit hyperactivity disorder	0.00177	0.00216	CbGpPWpGaD
Mivacurium—CHRNA2—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.00175	0.00215	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Other—DRD3—attention deficit hyperactivity disorder	0.00175	0.00214	CbGpPWpGaD
Mivacurium—CHRNA2—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.00173	0.00212	CbGpPWpGaD
Mivacurium—CHRNA2—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.00172	0.00211	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Other—DRD4—attention deficit hyperactivity disorder	0.00171	0.0021	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Other—DRD4—attention deficit hyperactivity disorder	0.0017	0.00208	CbGpPWpGaD
Mivacurium—CHRND—Neuronal System—COMT—attention deficit hyperactivity disorder	0.00164	0.00201	CbGpPWpGaD
Mivacurium—CHRNA1—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.00164	0.00201	CbGpPWpGaD
Mivacurium—CHRM3—Integration of energy metabolism—SNAP25—attention deficit hyperactivity disorder	0.00164	0.002	CbGpPWpGaD
Mivacurium—CHRND—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.00163	0.002	CbGpPWpGaD
Mivacurium—BCHE—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.00158	0.00193	CbGpPWpGaD
Mivacurium—CHRNA2—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.00156	0.00191	CbGpPWpGaD
Mivacurium—CHRM3—Integration of energy metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00156	0.00191	CbGpPWpGaD
Mivacurium—CHRM2—G alpha (i) signalling events—ADRA2C—attention deficit hyperactivity disorder	0.00153	0.00187	CbGpPWpGaD
Mivacurium—CHRM2—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.00147	0.0018	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00144	0.00176	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00142	0.00174	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00141	0.00172	CbGpPWpGaD
Mivacurium—CHRM3—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00141	0.00172	CbGpPWpGaD
Mivacurium—CHRNA1—Neuronal System—COMT—attention deficit hyperactivity disorder	0.0014	0.00171	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.0014	0.00171	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00139	0.0017	CbGpPWpGaD
Mivacurium—CHRM2—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00139	0.0017	CbGpPWpGaD
Mivacurium—CHRNA1—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.00139	0.0017	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00138	0.00169	CbGpPWpGaD
Mivacurium—BCHE—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.00136	0.00166	CbGpPWpGaD
Mivacurium—CHRNA2—Neuronal System—COMT—attention deficit hyperactivity disorder	0.00133	0.00163	CbGpPWpGaD
Mivacurium—CHRNA2—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.00132	0.00161	CbGpPWpGaD
Mivacurium—BCHE—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.00126	0.00155	CbGpPWpGaD
Mivacurium—CHRM2—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.00126	0.00154	CbGpPWpGaD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00123	0.0015	CbGpPWpGaD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00122	0.00149	CbGpPWpGaD
Mivacurium—BCHE—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00121	0.00148	CbGpPWpGaD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.0012	0.00147	CbGpPWpGaD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00119	0.00146	CbGpPWpGaD
Mivacurium—CHRM2—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.00117	0.00144	CbGpPWpGaD
Mivacurium—CHRM2—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.00117	0.00144	CbGpPWpGaD
Mivacurium—BCHE—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.00113	0.00138	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Other—HTR2A—attention deficit hyperactivity disorder	0.00112	0.00137	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Other—HTR2A—attention deficit hyperactivity disorder	0.00111	0.00136	CbGpPWpGaD
Mivacurium—BCHE—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.00104	0.00127	CbGpPWpGaD
Mivacurium—CHRM2—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.00104	0.00127	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000974	0.00119	CbGpPWpGaD
Mivacurium—BCHE—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.000967	0.00118	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000965	0.00118	CbGpPWpGaD
Mivacurium—BCHE—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.000957	0.00117	CbGpPWpGaD
Mivacurium—BCHE—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.00095	0.00116	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000936	0.00115	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000927	0.00113	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000917	0.00112	CbGpPWpGaD
Mivacurium—CHRM2—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.000909	0.00111	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000908	0.00111	CbGpPWpGaD
Mivacurium—CHRM2—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.000883	0.00108	CbGpPWpGaD
Mivacurium—BCHE—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.000862	0.00106	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000852	0.00104	CbGpPWpGaD
Mivacurium—CHRM2—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.000851	0.00104	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000843	0.00103	CbGpPWpGaD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000835	0.00102	CbGpPWpGaD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000827	0.00101	CbGpPWpGaD
Mivacurium—CHRM2—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.000818	0.001	CbGpPWpGaD
Mivacurium—CHRM2—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.000804	0.000985	CbGpPWpGaD
Mivacurium—CHRM2—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.000794	0.000972	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000792	0.000969	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000789	0.000966	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000784	0.00096	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000781	0.000956	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000767	0.000939	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000759	0.00093	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000754	0.000923	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000747	0.000914	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000745	0.000911	CbGpPWpGaD
Mivacurium—CHRM2—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.00074	0.000906	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000737	0.000902	CbGpPWpGaD
Mivacurium—BCHE—Neuronal System—COMT—attention deficit hyperactivity disorder	0.000733	0.000897	CbGpPWpGaD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00073	0.000893	CbGpPWpGaD
Mivacurium—BCHE—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.000728	0.000891	CbGpPWpGaD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000723	0.000885	CbGpPWpGaD
Mivacurium—CHRM2—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.000719	0.000881	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000716	0.000877	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000709	0.000868	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000694	0.000849	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000687	0.000841	CbGpPWpGaD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000678	0.00083	CbGpPWpGaD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000672	0.000822	CbGpPWpGaD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000657	0.000804	CbGpPWpGaD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000651	0.000796	CbGpPWpGaD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000646	0.00079	CbGpPWpGaD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00064	0.000783	CbGpPWpGaD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000638	0.000781	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000636	0.000778	CbGpPWpGaD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000632	0.000773	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00063	0.000771	CbGpPWpGaD
Mivacurium—CHRM3—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.000628	0.000769	CbGpPWpGaD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000594	0.000727	CbGpPWpGaD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000588	0.00072	CbGpPWpGaD
Mivacurium—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.000562	0.000688	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000556	0.00068	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00055	0.000674	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000529	0.000648	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000524	0.000641	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000518	0.000634	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000517	0.000632	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000513	0.000628	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000512	0.000626	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.0005	0.000612	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000495	0.000606	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000492	0.000602	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000487	0.000596	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000486	0.000595	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000486	0.000595	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000481	0.000589	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000481	0.000589	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00048	0.000588	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000476	0.000582	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000471	0.000576	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000466	0.000571	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000452	0.000554	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000448	0.000548	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000441	0.00054	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000423	0.000518	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000419	0.000513	CbGpPWpGaD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000416	0.000509	CbGpPWpGaD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000412	0.000504	CbGpPWpGaD
Mivacurium—CHRM2—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.000381	0.000467	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000359	0.00044	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000356	0.000435	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000339	0.000415	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00033	0.000404	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000327	0.0004	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000326	0.000399	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000323	0.000395	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000317	0.000388	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000314	0.000384	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000314	0.000384	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000311	0.000381	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000305	0.000373	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000305	0.000373	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—DPYD—attention deficit hyperactivity disorder	0.0003	0.000367	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000292	0.000357	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000289	0.000354	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000285	0.000349	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000284	0.000347	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000283	0.000346	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000282	0.000346	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000281	0.000344	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00028	0.000343	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000279	0.000341	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000278	0.00034	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000278	0.00034	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000275	0.000337	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000275	0.000337	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000275	0.000336	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000273	0.000334	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000272	0.000333	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00027	0.000331	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000265	0.000325	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000263	0.000321	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000257	0.000314	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000256	0.000313	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000254	0.000311	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000253	0.00031	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000252	0.000309	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00025	0.000306	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000249	0.000305	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000247	0.000302	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000244	0.000298	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000234	0.000287	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000234	0.000287	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000232	0.000284	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000232	0.000284	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000231	0.000282	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00023	0.000281	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000214	0.000262	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000193	0.000236	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000191	0.000234	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000187	0.000229	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—COMT—attention deficit hyperactivity disorder	0.000185	0.000226	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000183	0.000224	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000179	0.000219	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000178	0.000218	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000178	0.000218	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000177	0.000217	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000168	0.000206	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000167	0.000204	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000163	0.000199	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000161	0.000197	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000157	0.000192	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000155	0.00019	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000152	0.000186	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.00015	0.000184	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000149	0.000182	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000148	0.000181	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000147	0.00018	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000146	0.000178	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—COMT—attention deficit hyperactivity disorder	0.000142	0.000174	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000141	0.000173	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000137	0.000168	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000136	0.000166	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	9.61e-05	0.000118	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	9.51e-05	0.000116	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—EP300—attention deficit hyperactivity disorder	7.92e-05	9.69e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—EP300—attention deficit hyperactivity disorder	6.09e-05	7.45e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.09e-05	6.23e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.04e-05	6.17e-05	CbGpPWpGaD
